Search clinical trials for: GW873140

Total 7 results

GlaxoSmithKline

Terminated

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects

HIV Infection

United States, Belgium
GlaxoSmithKline

Terminated

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

HIV Infection

United States, Germany, Belgium, Canada, Denmark
ViiV Healthcare
GlaxoSmithKline

Terminated

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

Infection, Human Immunodeficiency Virus I

United States, Canada, Puerto Rico
GlaxoSmithKline

Terminated

Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

HIV Infection

Germany
National Institute of Allergy and Infectious Diseases...

Completed

GW873140 to Treat HIV-1 Infected Adults

HIV Infections

United States
ViiV Healthcare

Terminated

GW873140 In Combination With Combivir In HIV Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, France, Canada, Germany, Italy, Belgium, United Kingdom, Portugal, Spain
ViiV Healthcare

Terminated

GW873140 In Combination With Kaletra In HIV Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Germany, France, Canada, Spain, Italy, Portugal, United Kingdom, Denmark, Netherlands

3

Subscribe